Literature DB >> 1722328

Isolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase.

V R Prasad1, I Lowy, T de los Santos, L Chiang, S P Goff.   

Abstract

The appearance of drug-resistant strains of viral pathogens is a major difficulty confounding current efforts to block viral infections. The identification and analysis of mutations responsible for drug resistance can provide important clues helpful in understanding the mechanisms of resistance and in the eventual development of better therapies. We have used a direct screening method to scan libraries of mutagenized genes encoding the reverse transcriptase of human immunodeficiency virus type 1, and have recovered a variant enzyme that is resistant to the chain-terminator inhibitor 2',3'-dideoxyguanosine triphosphate. The single substitution mutation in this variant conferred broad crossresistance to a variety of other antiviral compounds currently in clinical trials. Virus carrying the mutation was fully infectious in cultured human lymphocytes. The replication of the mutant virus was highly resistant to phosphonoformic acid but did not show increased resistance to the prodrug dideoxyguanosine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722328      PMCID: PMC53135          DOI: 10.1073/pnas.88.24.11363

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Initial clinical experience with dideoxynucleosides as single agents and in combination therapy.

Authors:  R Yarchoan; J M Pluda; C F Perno; H Mitsuya; R V Thomas; K M Wyvill; S Broder
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Expression of enzymatically active reverse transcriptase in Escherichia coli.

Authors:  N Tanese; M Roth; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

Review 3.  Inhibitors of retroviral DNA polymerase: their implication in the treatment of AIDS.

Authors:  P Chandra; A Vogel; T Gerber
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

4.  Determination of the mutation rate of a retrovirus.

Authors:  J M Leider; P Palese; F I Smith
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

5.  Construction of recombinant murine retroviruses that express the human T-cell leukemia virus type II and human T-cell lymphotropic virus type III trans activator genes.

Authors:  C A Rosen; J G Sodroski; K Campbell; W A Haseltine
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

6.  Domain structure of the Moloney murine leukemia virus reverse transcriptase: mutational analysis and separate expression of the DNA polymerase and RNase H activities.

Authors:  N Tanese; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

7.  Linker insertion mutagenesis of the human immunodeficiency virus reverse transcriptase expressed in bacteria: definition of the minimal polymerase domain.

Authors:  V R Prasad; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Conditional mutator gene in Escherichia coli: isolation, mapping, and effector studies.

Authors:  G E Degnen; E C Cox
Journal:  J Bacteriol       Date:  1974-02       Impact factor: 3.490

9.  Determination of the rate of base-pair substitution and insertion mutations in retrovirus replication.

Authors:  J P Dougherty; H M Temin
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

10.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

View more
  30 in total

1.  A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Authors:  R A Smith; G J Klarmann; K M Stray; U K von Schwedler; R F Schinazi; B D Preston; T W North
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions.

Authors:  R F Schinazi; R M Lloyd; C S Ramanathan; E W Taylor
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 3.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro.

Authors:  W C Drosopoulos; V R Prasad
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Identification of an active reverse transcriptase enzyme encoded by a human endogenous HERV-K retrovirus.

Authors:  B Berkhout; M Jebbink; J Zsíros
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

6.  The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.

Authors:  Y Kew; H Salomon; L R Olsen; M A Wainberg; V R Prasad
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

7.  A screen in Escherichia coli for nucleoside analogs that target human immunodeficiency virus (HIV) reverse transcriptase: coexpression of HIV reverse transcriptase and herpes simplex virus thymidine kinase.

Authors:  B Kim; L A Loeb
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Authors:  J W Mellors; H Z Bazmi; R F Schinazi; B M Roy; Y Hsiou; E Arnold; J Weir; D L Mayers
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

9.  A positively charged side chain at position 154 on the beta8-alphaE loop of HIV-1 RT is required for stable ternary complex formation.

Authors:  Bechan Sharma; Neerja Kaushik; Alok Upadhyay; Snehlata Tripathi; Kamalendra Singh; Virendra N Pandey
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

10.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.